{"nctId":"NCT00468728","briefTitle":"PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","startDateStruct":{"date":"2006-10-04","type":"ACTUAL"},"conditions":["Clostridium Infections","Diarrhea"],"count":535,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vancomycin"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: PAR-101/OPT-80"]}],"interventions":[{"name":"PAR-101/OPT-80","otherNames":[]},{"name":"Vancomycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males/females with CDAD\n* Females must use adequate contraception\n* Signed informed consent\n\nExclusion Criteria:\n\n* Life-threatening CDAD\n* Toxic megacolon\n* Pregnant\n* Concurrent use of diarrheal agents\n* Participation in other trials","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cure Rate at End of Therapy","description":"Percentage of subjects with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence","description":"Percentage of subjects with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Cure","description":"Achieving a cure response at end of treatment and not having a recurrence at any time up to the post-study visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"76.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":260},"commonTop":["NAUSEA","VOMITING","ABDOMINAL PAIN","HYPOKALAEMIA","HEADACHE"]}}}